Experience
Eli Lilly and Company
Teva Pharmaceuticals International
Represented Eli Lilly in multiple inter partes reviews (IPRs) involving antibody patents.
Eli Lilly and Company v. Teva Pharmaceuticals International, IPR2018-01422; -01423; -01424; -01425; -01426; -01427; -01710, -01711, -01712, PTAB
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Eli Lilly and Company
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Eli Lilly and Company
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.
Eli Lilly and Company
Eli Lilly and Company v. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Eli Lilly and Company
IntelGenX Corporation v. Eli Lilly and Company; ICOS Corporation
Eli Lilly and Company; ICOS Corporation
Eli Lilly and Company v. Genentech, Inc.
Eli Lilly and Company
Eli Lilly and Company v. Actavis Labs. UT Inc.
Eli Lilly and Company
Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista®
Eli Lilly and Company
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.